CSIMarket


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 

Integrated Biopharma Inc

INBP's Fundamental analysis








Integrated Biopharma Inc's sales fell by -6.49 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 1695

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -0.33 %

Integrated Biopharma Inc's net income grew by 1681.25 % in III. Quarter 2024 year on year, above company average,

More on INBP's Growth


Integrated Biopharma Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Integrated Biopharma Inc realized cash outflow of $ -0.02per share in trailing twelve-month period.
Company
359.12
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.16.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.45.


More on INBP's Valuation
 
 Total Debt (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 11.2
 Tangible Book Value (Per Share $) 0.61

Integrated Biopharma Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Integrated Biopharma Inc realized cash outflow of $ -0.02per share in trailing twelve-month period.
Company
359.12
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.16.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.45.

Integrated Biopharma Inc Price to Book Ratio is at 0.41 lower than Indusry Avg. of 76.56. and higher than S&P 500 Avg. of 0.01

More on INBP's Valuation

  Market Capitalization (Millions $) 8
  Shares Outstanding (Millions) 31
  Employees -
  Revenues (TTM) (Millions $) 48
  Net Income (TTM) (Millions $) 0
  Cash Flow (TTM) (Millions $) -1
  Capital Exp. (TTM) (Millions $) 0
  Total Debt (Millions $) 0
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ -
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) 11.2
  Tangible Book Value (Per Share $) 0.61

  Market Capitalization (Millions $) 8
  Shares Outstanding (Millions) 31
  Employees -
  Revenues (TTM) (Millions $) 48
  Net Income (TTM) (Millions $) 0
  Cash Flow (TTM) (Millions $) -1
  Capital Exp. (TTM) (Millions $) 0


    INBP's Profitability Comparisons
Integrated Biopharma Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 2.9 %.

Integrated Biopharma Inc net profit margin of 2.33 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 126 in Healthcare sector and number 1737 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 2.63
  Total Debt to Equity (MRQ) 0
  Tangible Leverage Ratio (MRQ) 0.42
  Asset Turnover Ratio (TTM) 1.95
  Inventory Turnover Ratio (TTM) 4.03



Integrated Biopharma Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 2.9 %.

Integrated Biopharma Inc net profit margin of 2.33 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 126 in Healthcare sector and number 1737 in S&P 500.

More on INBP's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com